Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma


Clinical Trial Description

This trial was a single-arm, multicenter phase Ⅱ clinical study. Eligible oligometastatic NPC patients were scheduled to evaluate the efficacy and tolerance of local consolidative radiotherapy combined with camrelizumab and chemotherapy in patients with oligometastatic NPC. Progression-free survival (PFS) determined will be the primary outcome measures. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05128201
Study type Interventional
Source Jiangxi Provincial Cancer Hospital
Contact
Status Not yet recruiting
Phase Phase 2
Start date December 1, 2021
Completion date May 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04617457 - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT05101824 - Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease N/A
Recruiting NCT04748042 - Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Phase 2
Recruiting NCT04973007 - Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases Phase 4
Recruiting NCT01345539 - Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation Phase 2
Not yet recruiting NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer N/A
Not yet recruiting NCT04724928 - Evaluating the Impact of FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer Phase 2
Completed NCT02264379 - Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma
Recruiting NCT04141709 - Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer N/A